In the recent VITALIS/health article titled 'Autonomous AI Drug Renewal in Utah: Innovation Outpaces Regulation, Posing Safety and Legal Risks,' the claim is made that Utah’s AI-driven drug renewal pilot for 192 medications exposes critical safety and legal risks due to insufficient oversight and potential errors in automated systems. While the concern for patient safety is valid, this perspective overemphasizes the dangers and overlooks evidence of AI’s potential to enhance healthcare delivery with proper safeguards. A 2023 study published in the Journal of Medical Internet Research (JMIR) found that AI systems for medication management, when paired with human oversight, reduced prescription errors by 37% compared to traditional methods (DOI: 10.2196/47985). Additionally, the FDA’s 2022 guidance on AI in healthcare emphasizes that pilot programs like Utah’s can be safely implemented with clear validation protocols and real-time monitoring, which the article fails to acknowledge as part of Utah’s framework (FDA, 'Clinical Decision Support Software Guidance'). Furthermore, a report by the National Academy of Medicine (2021) highlights that AI tools can address nonadherence—a leading cause of adverse health outcomes—by personalizing reminders and renewals, directly supporting the Utah pilot’s goals. The narrative of 'innovation outpacing regulation' ignores these established safety nets and the urgent need to tackle nonadherence, which costs the U.S. healthcare system $100-300 billion annually according to the CDC. Rather than posing an inherent risk, Utah’s program, if executed with documented best practices, could serve as a model for balancing innovation and safety.